The kinetics of cancer cells and of HIV1: The problems of cell and virus rebounds and of latency

Biomedicine and Pharmacotherapy

Volumn 52, Issue 10, 1998, Pages 413-420

  Mathe, G ^a  

^a Hopital Suisse de Paris   (France)

Author keywords

Cancer cells; HIV1; Oncostatics; Treatment; Virostatics

Indexed keywords

ACRIFLAVINE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ELLIPTICINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER CELL; CELL KILLING; CELL PROLIFERATION; CYTOSTASIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENETICS; LATENT VIRUS INFECTION; METHYLATION; PRIORITY JOURNAL; REVIEW; VIRUS EXPRESSION; VIRUS REACTIVATION;

EID: 0032321609     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(99)80018-3     Document Type: Editorial

References (49)

1. Mathé G Is the “war against cancer” lost ? Biomed Pharmacother 46 1992 433
2. 1 particle cure AIDS patients? Doesn't CMV activation and/or a graft-versus-host component of the disease, also have to be considered ? First of two parts Biomed Pharmacother 50 1996 185
3. Skipper HE Cellular kinetics associated with “curability” of experimental leukemias Dammsheck W Dutcher RM Perspectives in leukemia vol 1 1968 Grune Stratton New York 187
4. Norton L Simon R Tumor size, sensitivity to therapy and design of treatment schedules Cancer Treat Rep 61 1977 1307
5. Eriguchi M Mathé G Analysis of survival and disease free survival curves for understanding the effect of adjuvant therapy of malignant disease Oncologia 12 1985 146
6. Stout SA Riley CM Derendorf H In vitro pharmacokinetics and pharmacodynamics of melphalan Biennial Conference on Chemotherapy in Infectious Disease Malignancies Munich 1987
7. Blum R Frei E Combination Chemotherapy Methods Cancer Res 17 1979 215
8. Clarysse A Kenis Y Mathé G Cancer Chemotherapy 1976 Springer New York
9. Mathé G Plagne R Moria V Misset JL Consistencies and variation of observation during serial analyses of a trial of adjuvant chemotherapy in breast cancer Adjuvant Therapy of Cancer 1987 Grune Stratton New York 271
10. Einhorn L Hand Williams SD The Management of disseminated testicular cancer Einhorn LH Testicular tumors 1980 Masson New York 117
11. Kovcin V, Cicmil-Saric N, Mathé G. Alternative cycle composition in advanced cancer chemotherapy. Submitted
12. Mathé G Pontiggia P Bourut C Chenu E Orbach-Ar-bouys S In vivo eradication of Friend virus as an experimental HIV-model, by combination of zidovudine, acriflavine and an ellipticine analogue. Possible application to the treatment of human pre-AIDS ? Biomed Pharmacother 52 1998 48 51
13. Mitsuya H Broder S Inhibition of the in vitro infectivity and cytopathic effect of human T-lytnphotropic virus type III/lymphadenopathy virus-associated virus (HTL-III/LAV) by 2′, 3-dideoxynucleosides Proc Natl Acad Sci USA 83 1986 1911 1915
14. Davis RH Williams H Smith HJ Intermolecular forces and stereospecificity in drug action Introduction to the Principal of Drug Design 1988 Wright London
15. Fosse P René B Le Bret M Sequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivative Nucleic Acids Res 19 1991 2861 2868
16. Mathé G Huppert J Chenu E Bourut C Amino-acridines action on Friend's virus retrovirus in relation to their molecular ionization Biomed Pharmacother 43 1989 235 236
17. Mathé G Chenu E Bourut C The in vivo effect of ellipticine analogues on the blood concentration of Friend's virus : a murine model for studying anti-HIV drugs Biomed Pharmacother 47 1993 457 460
18. Mathé G Chenu E Bourut C Virostatic in vivo effect of elliptinium on Friend's virus retrovirus infection (a model of HIV infection) Biomed Pharmacother 44 1990 1 3
19. Mathé G Pontiggia P A screening model of anti-HIV non AZT cross resistant virostatics Biomed Pharmacother 47 1993 461 462
20. 1-AIDS complex Biomed Pharmacother 50 1996 510 511
21. Mathé G Morette C Hallard M Blanquet D Combinations of three or four HIV, virostatics applied in short sequences which differ from each other by drug rotation. Preliminary results of the viral loads and CD4 numbers Biomed Pharmacother 51 1997 417 426
22. Mathé G Pontiggia P Orbach-Arbouys S AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts : a phase I trial equivalent, concerning five virostatics : AZT, ddI, acriflavine and an ellipticine analogue Biomed Pharmacother 50 1996 220 227
23. Di YP Repasky EA Subjeck JR Distribution of HSP70, protein kinase C, and spectrin is altered in lymphocytes during a fever-like hyhyperthermia exposure J Cell Physiol 172 1997 44 54
24. Mathé G Canon C Goutner A Ogier C Reizeinstein The common acute lymphoid antigen in blood marrow and lymph nodes in lymphoid malignancy at diagnosis and in remission 5th Intern Immunol Kyoto 8 1983 21 27
25. Coustan-Smith E Behm FG Sanchez J Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia Lancet 351 1998 550 554
26. Salahuddin SZ Ablashi DV Markham PD Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders Science 234 1986 596 601
27. Daibata M Taguchi T Kamioka M Kubonishi I Taguchi H Miyoshi I Identification of integrated human herpes-virus 6 DNA in early pre-B cell acute lymphoblastic leukemia Leukemia 12 1998 1002 1005
28. Razzaque A Oncogenic potential of human herpes virus 6 DNA Oncogene 5 1990 1365 1370
29. Luxton JC William I Weller I Epstein-Barr virus infection of HIV-seropositive individuals is transiently suppressed by high dose of acyclovir treatment AIDS 7 1993 1337
30. Farrell PJ Cludts I Stühler A Epstein-Barr virus genes and Cancer cells Biomed. Pharmacother 51 1997 258
31. Oettle H Wilborn F Schmidt C Treatment with ganclovir and Ig for acute Epstein-Barr virus infection after allogenic bone marrow transplantation Blood 82 1993 2257
32. Uhr JW Richard H Schemerman S Cancer dormancy : opportunity for a new therapeutic approaches Nature Med 3 1997 505
33. 1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent, viral structure Cell 61 1990 213
34. Robertson KD Mann A Swinnen LJ GpG methylation of the major Epstein-Barr virus latency promotor in Burkitt's lyses lymphomas and Hodgkin's diseases Blood 88 1996 3129
35. 1-infection Science 254 1991 423
36. Starzl TE Porter KA Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy Lancet 1 1984 583
37. Josephson D Antiretroviral combinations do not eliminate HIV entirely BMJ 315 1997 7121
38. Mathé G Cancer active immunotherapy, immunoprophylaxis and immunorestoration 1976 Springer Berlin
39. Komada Y Azuma E Yamamoto S Sakurai M Discontinuing chemoimmunotherapy in childhood acute lymphoblastic leukemia Biomed Pharmacother 42 1998 597 604
40. Tursz T Hors J Lipinski M Amiel JL Mathé G Comparison of HLA phenotype in long-term survivors with acute lymphoid leukemia treated with immunotherapy versus chemotherapy Mathé G Bannoda G Salmon S Adjuvant Therapies of Cancer 1982 Springer Berlin
41. Mathé G Le SIDA 1976 La Gutillerie Paris
42. Les survivants à long terme Quot Med 1993 5
43. Kim JP Immunochemosurgery as a new approach to reasonable treatment of advanced p138 in Current study of Cancer control and Immunobiology Proc 8th Pacific Cancer Conf Seoul 1987
44. 1 p 24 antigen reappears in the blood Biomed Pharmacother 48 1994 3
45. Terry
46. Mathé G Cancer “cures” in Children adolescent and young adults versus general cancer cure failure after 50 years of age Biomed Pharmacother 42 1988 227
47. Abel Y Chemotherapy of advanced epithelial cancer—a critical review Biomed Pharmacother 46 1992 439
48. Mathé G Hypothetical reasons of the HIV1-AIDS “tritherapy” failure. A challenging model Biomed Pharmacother 51 1997 413
49. Ho D The molecular medicine revolution Nature Medicine 4 1998 1939